Deconstructing innate immune signaling in myelodysplastic syndromes

Experimental Hematology

Volumn 43, Issue 8, 2015, Pages 587-598

  Varney, Melinda E ^a   Melgar, Katelyn ^a   Niederkorn, Madeline ^a,b   Smith, Molly A ^a,b   Barreyro, Laura ^a   Starczynowski, Daniel T ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 6; INTERLEUKIN 8; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

CYTOKINE PRODUCTION; CYTOKINE RELEASE; GAIN OF FUNCTION MUTATION; GENE OVEREXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; INNATE IMMUNITY; INTRINSIC ACTIVITY; MEDIATOR RELEASE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; GENETICS; IMMUNOLOGY; MOUSE; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNITY, INNATE; MICE; MYELODYSPLASTIC SYNDROMES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84939209648     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.05.016     Document Type: Review

References (146)

1. Tehranchi R., Woll P.S., Anderson K., et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 2010, 363:1025-1037.
2. Will B., et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 2012, 120:2076-2086.
3. Will B., Zhou L., Vogler T.O., et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 2014, 25:794-808.
4. Nilsson L., Astrand-Grundström I., Arvidsson I., et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000, 96:2012-2021.
5. Nilsson L., Edén P., Olsson E., et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q-myelodysplastic syndromes. Blood 2007, 110:3005-3014.
6. Nilsson L., Astrand-Grundström I., Anderson K., et al. Involvement and functional impairment of the CD34+CD38-Thy-1+ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002, 100:259-267.
7. Corey S.J., Minden M.D., Barber D.L., Kantarjian H., Wang J.C., Schimmer A.D. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007, 7:118-129.
8. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
9. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
10. Walter M.J., Shen D., Ding L., et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012, 366:1090-1098.
11. Cazzola M., Malcovati L. Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin North Am 2010, 24:459-468.
12. Hofmann W.K., de Vos S., Komor M., Hoelzer D., Wachsman W., Koeffler H.P. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002, 100:3553-3560.
13. Pellagatti A., Cazzola M., Giagounidis A., et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010, 24:756-764.
14. Kristinsson S.Y., Björkholm M., Hultcrantz M., Derolf Å.R., Landgren O., Goldin L.R. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011, 29:2897-2903.
15. Rhyasen G.W., Bolanos L., Fang J., et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 2013, 24:90-104.
16. Gañán-Gómez I., Wei Y., Yang H., et al. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest. PLoS One 2014, 9:e93404.
17. Yang L., Qian Y., Eksioglu E., Epling-Burnette P., Wei S. The inflammatory microenvironment in MDS. Cell Mol Life Sci 2015, 72:1959-1966.
18. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
19. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
20. Moresco E.M.Y., LaVine D., Beutler B. Toll-like receptors. Curr Biol 2011, 21:R488-R493.
21. Boiko J.R., Borghesi L. Hematopoiesis sculpted by pathogens: toll-like receptors and inflammatory mediators directly activate stem cells. Cytokine 2012, 57:1-8.
22. Sioud M., Fløisand Y. TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response. Eur J Immunol 2007, 37:2834-2846.
23. Takizawa H., Regoes R.R., Boddupalli C.S., Bonhoeffer S., Manz M.G. Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. J Exp Med 2011, 208:273-284.
24. Esplin B.L., Shimazu T., Welner R.S., et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol 2011, 186:5367-5375.
25. Zhao Y., Ling F., Wang H.C., Sun X.H. Chronic TLR signaling impairs the long-term repopulating potential of hematopoietic stem cells of wild type but not Id1 deficient mice. PLoS One 2013, 8:e55552.
26. Maratheftis C.I., Andreakos E., Moutsopoulos H.M., Voulgarelis M. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res 2007, 13:1154-1160.
27. Kuninaka N., Kurata M., Yamamoto K., et al. Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia. Exp Mol Pathol 2010, 88:293-298.
28. Wei Y., Dimicoli S., Bueso-Ramos C., et al. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia 2013, 27:1832-1840.
29. Nishiya T., Kajita E., Horinouchi T., Nishimoto A., Miwa S. Distinct roles of TIR and nonTIR regions in the subcellular localization and signaling properties of MyD88. FEBS Lett 2007, 581:3223-3229.
30. Wesche H., Henzel W.J., Shillinglaw W., Li S., Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997, 7:837-847.
31. Loiarro M., Volpe E., Ruggiero V., et al. Mutational analysis identifies residues crucial for homodimerization of myeloid differentiation factor 88 (MyD88) and for its function in immune cells. J Biol Chem 2013, 288:30210-30222.
32. Lin S.-C., Lo Y.-C., Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 2010, 465:885-890.
33. Motshwene P.G., Moncrieffe M.C., Grossmann J.G., et al. An Oligomeric Signaling Platform formed by the toll-like receptor signal transducers MyD88 and IRAK-4. J Biol Chem 2009, 284:25404-25411.
34. Häcker H., Redecke V., Blagoev B., et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 2006, 439:204-207.
35. Xia Z.P., Sun L., Chen X., et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009, 461:114-119.
36. Hou B, Reizis B, DeFranco AL. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity. 2008;29:272-282.
37. Xu L., Hunter Z.R., Yang G., et al. MYD88 L265P in Waldenstrom's macroglobulinemia, IgM monoclonal gammopathy, and other b-cell lymphoproliferative disorders using conventional and quantitative allele-specific PCR. Blood 2013, 121:2051-2058.
38. Zagaria A., Coccaro N., Tota G., et al. Myelodysplastic syndrome with 5q deletion following IgM monoclonal gammopathy, showing gene mutation MYD88 L265P. Blood Cells Mol Dis 2015, 54:51-52.
39. Avbelj M., Wolz O.O., Fekonja O., et al. Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization. Blood 2014, 124:3896-3904.
40. Dimicoli S., Wei Y., Bueso-Ramos C., et al. Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. PLoS One 2013, 8:e71120.
41. Schinke C., Giricz O., Li W., et al. IL-8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood 2015, 125:3144-3152.
42. Horng T., Barton G.M., Flavell R.A., Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002, 420:329-333.
43. Fitzgerald K.A., Palsson-McDermott E.M., Bowie A.G., et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001, 413:78-83.
44. Horng T., Barton G.M., Medzhitov R.T.I.R.A.P. an adapter molecule in the Toll signaling pathway. Nat Immunol 2001, 2:835-841.
45. Bonham K.S., Orzalli M.H., Hayashi K., et al. A promiscuous lipid-binding protein diversifies the subcellular sites of toll-like receptor signal transduction. Cell 2014, 156:705-716.
46. Equils O., Madak Z., Liu C., Michelsen K.S., Bulut Y., Lu D. Rac1 and Toll-IL-1 receptor domain-containing adapter protein mediate Toll-like receptor 4 induction of HIV-long terminal repeat. J Immunol 2004, 172:7642-7646.
47. Verstak B., Nagpal K., Bottomley S.P., Golenbock D.T., Hertzog P.J., Mansell A. MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-κB proinflammatory responses. J Biol Chem 2009, 284:24192-24203.
48. Mellett M., Atzei P., Jackson R., O'Neill L.A., Moynagh P.N. Mal mediates TLR-induced activation of CREB and expression of IL-10. J Immunol 2011, 186:4925-4935.
49. Starczynowski D.T., Kuchenbauer F., Argiropoulos B., et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010, 16:49-58.
50. Ibrahim R, Wegrzyn J, Chang LYT, et al. Activation of non-canonical immune sigaling pathways drives bone marrow failure in murine model of MDS. Paper presented at: 56th ASH Annual Meeting and Exposition; December, 2014; San Francisco, CA, USA.
51. Lam J, Wegrzyn-Woltosz J, Ibrahim R, et al. Loss of MiR-143 and MiR-145 inhibits hematopoietic stem cell self-renewal through dysregulated TGFβ signaling. Paper presented at: 56th ASH Annual Meeting and Exposition; December, 2014; San Francisco, CA, USA.
52. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
53. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
54. Smith D.E. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010, 40:200-208.
55. Gabay C., McInnes I.B. The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases. Arthritis Res Ther 2009, 11:230.
56. Cullinan E.B., Kwee L., Nunes P., et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol 1998, 161:5614-5620.
57. Greenfeder S.A., Nunes P., Kwee L., Labow M., Chizzonite R.A., Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 1995, 270:13757-13765.
58. Hofmeister R., Wiegmann K., Korherr C., Bernardo K., Krönke M., Falk W. Activation of acid sphingomyelinase by interleukin-1 (IL-1) requires the IL-1 receptor accessory protein. J Biol Chem 1997, 272:27730-27736.
59. Korherr C., Hofmeister R., Wesche H., Falk W.A. Critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol 1997, 27:262-267.
60. Huang J., Gao X., Li S., Cao Z. Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc Natl Acad Sci U S A 1997, 94:12829-12832.
61. Jefferies C., Bowie A., Brady G., Cooke E.L., Li X., O'Neill L.A. Transactivation by the p65 subunit of NF-kappaB in response to interleukin-1 (IL-1) involves MyD88, IL-1 receptor-associated kinase 1, TRAF-6, and Rac1. Mol Cell Biol 2001, 21:4544-4552.
62. Brikos C., Wait R., Begum S., O'Neill L.A.J., Saklatvala J. Mass spectrometric analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components. Mol Cell Proteomics 2007, 6:1551-1559.
63. Barnes P.J., Karin M. Nuclear factor- kappa B-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336:1066-1071.
64. O'Neill L.A. Toward an understanding of the signal transduction pathways for interleukin 1. Biochim Biophys Acta 1995, 1266:31-44.
65. O'Neill L.A. Molecular mechanisms underlying the actions of the pro-inflammatory cytokine interleukin 1. Biochem Soc Trans 1997, 25:295-302.
66. O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008, 226:10-18.
67. Lang D., Knop J., Wesche H. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol 1998, 161:6871-6877.
68. Malinowsky D., Lundkvist J., Layé S., Bartfai T. Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett 1998, 429:299-302.
69. Ali S., Huber M., Kollewe C., Bischoff S.C., Falk W., Martin M.U. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A 2007, 104:18660-18665.
70. Chackerian A.A., Oldham E.R., Murphy E.E., Schmitz J., Pflanz S., Kastelein R.A. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007, 179:2551-2555.
71. Palmer G., Lipsky B.P., Smithgall M.D., et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008, 42:358-364.
72. Drube S., Heink S., Walter S., et al. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 2010, 115:3899-3906.
73. Towne J.E., Garka K.E., Renshaw B.R., Virca G.D., Sims J.E. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kB and MAPKs. J Biol Chem 2004, 279:13677-13688.
74. Sizemore N., Leung S., Stark G.R. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 1999, 19:4798-4805.
75. Ruhul Amin A.R., Machida K., Oshima K., et al. A role for SHPS-1/SIRPalpha1 in IL-1beta- and TNFalpha-dependent signaling. Oncogene 2002, 21:8871-8878.
76. Smith D.E., Hanna R., Friend Della, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 2003, 18:87-96.
77. Barreyro L., Will B., Bartholdy B., et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012, 120:1290-1298.
78. Askmyr M., Ågerstam H., Hansen N., et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 2013, 121:3709-3713.
79. Gerber J.M., Gucwa J.L., Esopi D., et al. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget 2013, 4:715-728.
80. Järås M., Johnels P., Hansen N., et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci U S A 2010, 107:16280-16285.
81. Zhao K., Yin L.L., Zhao D.M., et al. IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients. Int J Clin Exp Med 2014, 7:4787-4798.
82. Nishida A., Andoh A., Imaeda H., Inatomi O., Shiomi H., Fujiyama Y. Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. Gut 2010, 59:531-541.
83. Michaud N., Al-Akoum M., Akoum A. Blood soluble interleukin 1 receptor accessory protein levels are consistently low throughout the menstrual cycle of women with endometriosis. Reprod Biol Endocrinol 2014, 12:51.
84. Bozaoglu K., Attard C., Kulkarni H., et al. Plasma levels of soluble interleukin 1 receptor accessory protein are reduced in obesity. J Clin Endocrinol Metab 2014, 99:3435-3443.
85. Smallridge R.C., Chindris A.M., Asmann Y.W., et al. RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma. J Clin Endocrinol Metab 2014, 99:E338-E347.
86. Barreyro L., Mitchell K., Will B., et al. Abstarct C225: IL1RAP as functionally relevant target for stem-cell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Mol Cancer Ther 2013, 12:C225.
87. Windheim M., Stafford M., Peggie M., Cohen P. Interleukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 receptor-associated kinase 1 to facilitate NEMO binding and the activation of IkappaBalpha kinase. Mol Cell Biol 2008, 28:1783-1791.
88. Kubo-Murai M., Hazeki K., Nigorikawa K., Omoto T., Inoue N. Hazeki O.IRAK-4-dependent degradation of IRAK-1 is a negative feedback signal for TLR-mediated NF-KB activation. J Biochem 2008, 143:295-302.
89. Keating S.E., Maloney G.M., Moran E.M., Bowie A.G. IRAK-2 participates in multiple Toll-like receptor signaling pathways to NFkappaB via activation of TRAF6 ubiquitination. J Biol Chem 2007, 282:33435-33443.
90. Su J., Zhang T., Tyson J., Li L. The interleukin-1 receptor-associated kinase M selectively inhibits the alternative, instead of the classical NFkappaB pathway. J Innate Immun 2009, 1:164-174.
91. Picard C., von Bernuth H., Ghandil P., et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Pediatrics 2010, 89:403-425.
92. Thomas J.A., Allen J.L., Tsen M., et al. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J Immunol 1999, 163:978-984.
93. Kawagoe T., Sato S., Matsushita K., et al. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 2008, 9:684-691.
94. Suzuki N., Suzuki S., Duncan G.S., et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 2002, 416:750-756.
95. Meylan E., Tschopp J. IRAK2 takes its place in TLR signaling. Nat Immunol 2008, 9:581-582.
96. Seki M., Kohno S., Newstead M.W., et al. Critical role of IL-1 receptor-associated kinase-M in regulating chemokine-dependent deleterious inflammation in murine influenza pneumonia. J Immunol 2010, 184:1410-1418.
97. Rhyasen G.W., Bolanos L., Starczynowski D.T. Differential IRAK signaling in hematologic malignancies. Exp Hematol 2013, 41:1005-1007.
98. Chaudhary D., Robinson S., Romero D. Recent advances in the discovery of small molecule inhibitors of interleukin 1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for In flammation and oncology disorders. J Med Chem 2015, 58:96-110.
99. Rhyasen G., Starczynowski D.T. IRAK signalling in cancer. Br J Cancer 2015, 112:232-237.
100. Hofmann R.M., Pickart C.M. Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell 1999, 96:645-653.
101. Deng L., Wang C., Spencer E., et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000, 103:351-361.
102. Fukushima T., Matsuzawa S., Kress C.L., et al. Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses. Proc Natl Acad Sci U S A 2007, 104:6371-6376.
103. Pulvino M., Liang Y., Oleksyn D., et al. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood 2012, 120:1668-1677.
104. Zhang X., Zhang J., Zhang L., van Dam H., ten Dijke P. UBE2O negatively regulates TRAF6-mediated NF-κB activation by inhibiting TRAF6 polyubiquitination. Cell Res 2013, 23:366-377.
105. Muroi M., Tanamoto K. TRAF6 distinctively mediates MyD88- and IRAK-1-induced activation of NF-kappaB. J Leukoc Biol 2008, 83:702-707.
106. Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., Chen Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001, 412:346-351.
107. Yang W.L., Wang J., Chan C.H., et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009, 325:1134-1138.
108. Conze D.B., Wu C.-J., Thomas J.A., Landstrom A., Ashwell J.D. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB activation. Mol Cell Biol 2008, 28:3538-3547.
109. Shi C.-S., Kehrl J.H. TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy. Sci Signal 2010, 3:ra42.
110. Opaluch A.M., Schneider M., Chiang C.Y., et al. Positive regulation of TRAF6-dependent innate immune responses by protein phosphatase PP1-γ. PLoS One 2014, 9:e89284.
111. Jiao S., Zhang Z., Li C., et al. The kinase MST4 limits inflammatory responses through direct phosphorylation of the adaptor TRAF6. Nat Immunol 2015, 16:246-257.
112. Fang J., Rhyasen G., Bolanos L., et al. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA 1. Blood 2012, 120:858-867.
113. Beg A.A., Sha W.C., Bronson R.T., Baltimore D. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes Dev 1995, 9:2736-2746.
114. Rupec R.A., Jundt F., Rebholz B., et al. Stroma-mediated dysregulation of myelopoiesis in mice lacking IκBα. Immunity 2005, 22:479-491.
115. Breccia M., Alimena G. NF-(kappa)B as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opin Ther Targets 2012, 14:1157-1176.
116. Taganov K.D., Boldin M.P., Chang K.-J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006, 103:12481-12486.
117. Zhao J.L., Starczynowski D.T. Role of microRNA-146a in normal and malignant hematopoietic stem cell function. Front Genet 2014, 5:219.
118. Votavova H., Grmanova M., Dostalova Merkerova M., et al. Differential expression of microRNAs in CD34+ cells of 5q- syndrome. J Hematol Oncol 2011, 4:1.
119. Sokol L., Caceres G., Volinia S., et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol 2011, 153:24-32.
120. Zhao J.L., Rao D.S., O'Connell R.M., Garcia-Flores Y., Baltimore D. MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice. Elife 2013, 2:e00537.
121. Lu L.F., Boldin M.P., Chaudhry A., et al. Function of miR-146a in controlling treg cell-mediated regulation of Th1 responses. Cell 2010, 142:914-929.
122. Boldin M.P., Taganov K.D., Rao D.S., et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011, 208:1189-1201.
123. Zhao J.L., Rao D.S., Boldin M.P., et al. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A 2011, 108:9184-9189.
124. De A., Dainichi T., Rathinam C.V., Ghosh S. The deubiquitinase activity of A20 is dispensable for NF-κB signaling. EMBO Rep 2014, 15:L775-L783.
125. Kool M., van Loo G., Waelput W., et al. The ubiquitin-editing protein a20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 2011, 35:82-96.
126. Lee E.G., Boone D.L., Chai S., et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000, 289:2350-2354.
127. Boone D.L., Turer E.E., Lee E.G., et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004, 5:1052-1060.
128. Vereecke L., Beyaert R., van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009, 30:383-391.
129. Hövelmeyer N., Reissig S., Xuan N.T., et al. A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur J Immunol 2011, 41:595-601.
130. Tavares R.M., Turer E.E., Liu C.L., et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 2010, 33:181-191.
131. Chu Y., Vahl J.C., Kumar D., et al. B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 2011, 117:2227-2236.
132. Hammer G.E., Turer E.E., Taylor K.E., et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol 2011, 12:1184-1193.
133. Matmati M., Jacques P., Maelfait J., et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 2011, 43:908-912.
134. Nagamachi A., Nakata Y., Ueda T., et al. Acquired deficiency of A20 results in rapid apoptosis, systemic inflammation, and abnormal hematopoietic stem cell function. PLoS One 2014, 9:e87425.
135. Nakagawa M., Thummar K., Mandelbaum J., Pasqualucci L., Rathinam C. Lack of the ubiquitin-editing enzyme A20 results in loss of hematopoietic stem cell quiescence. J Exp Med 2015, 212:203-216.
136. Wertz I.E., O'Rourke K.M., Zhou H., et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004, 430:694-699.
137. Lu T.T., Onizawa M., Hammer G.E., et al. Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 2013, 38:896-905.
138. Bosanac I., Wertz I.E., Pan B., et al. Ubiquitin binding to A20 ZnF4 is required for modulation of NF-κB signaling. Mol Cell 2010, 40:548-557.
139. Tokunaga F., Nishimasu H., Ishitani R., et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation. EMBO J 2012, 31:3856-3870.
140. Tewari M., Wolf F.W., Seldin M.F., O'Shea K.S., Dixit V.M., Turka L.A. Lymphoid expression and regulation of A20, an inhibitor of programmed cell death. J Immunol 1995, 154:1699-1706.
141. Jaiswal S., Fontanillas P., Flannick J., et al. Age related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014, 371:2488-2498.
142. Honma K., Tsuzuki S., Nakagawa M., et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of nonHodgkin lymphomas. Blood 2009, 114:2467-2475.
143. Nocturne G., Boudaoud S., Miceli-Richard C., et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Blood 2013, 122:4068-4076.
144. Wei Y., Chen R., Dimicoli S., et al. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia 2013, 27:2177-2186.
145. Bar M., Stirewalt D., Pogosova-Agadjanyan E., et al. Gene expression pattern in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression. Transl Oncogenomics 2008, 3:137-149.
146. Kim S.W., Ramasamy K., Bouamar H., Lin A.P., Jiang D., Aguiar R.C. MicroRNAs miR-125a and miR-125b constitutively activate the NF- B pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A 2012, 109:7865-7870.